Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

OBJECTIVE: This study assessed the efficacy and safety of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, for prophylaxis against acute gouty arthritis flares in patients initiating urate-lowering treatment. METHODS: In this double-blind, double-dummy, dose-ranging study, 432 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlesinger, Naomi, Mysler, Eduardo, Lin, Hsiao-Yi, De Meulemeester, Marc, Rovensky, Jozef, Arulmani, Udayasankar, Balfour, Alison, Krammer, Gerhard, Sallstig, Peter, So, Alexander
Formato: Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103669/
https://www.ncbi.nlm.nih.gov/pubmed/21540198
http://dx.doi.org/10.1136/ard.2010.144063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103669/
https://www.ncbi.nlm.nih.gov/pubmed/21540198
http://dx.doi.org/10.1136/ard.2010.144063

Ejemplares similares